Skip to main content
OpenTrials
Completed

NCT Number: NCT04259008

Safety of Manganese Restriction in Neonatal Parenteral Nutrition

Participants will be <= 32 weeks gestational age (GA) neonates randomized to parenteral nutrition (PN) prepared with standard dose trace elements or to PN prepared with standard trace elements minus manganese.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 1 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sharp Mary Birch Hospital for Women and Newborns

San Diego, California, 92123, United States

About this study

Very preterm neonates <= 32+6 weeks GA receiving PN will be randomized to receive their PN prepared with standard trace elements containing 5 mcg/kg/day of manganese, or to PN prepared with no added manganese. Randomization assignment will be double masked. All participants will have whole blood manganese measurements at baseline, at 2 weeks of postnatal age, and at 8 weeks postnatal age. Because manganese is present as a contaminant in many of the ingredients used to prepare neonatal PN, this study hypothesizes that neonates randomized to no added manganese in their PN will maintain whole blood manganese concentrations above the lower limit of normal.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inborn admissions to the SHARP Mary Birch Hospital for Women and Newborns neonatal intensive care unit.
  • Less than or equal to 32+6 weeks gestational age.
  • Initiated on parenteral nutrition as decided by their attending neonatologist.

Exclusion criteria

  • Continuous exposure to routine care PN containing standard trace element for ≥ 4 hours.
  • Congenital liver disease.
  • Moribund status or imminent death.
  • Any condition that in the judgment of the investigator or attending physician provider precludes participation because it could affect subject safety.
  • Lack or refusal of informed consent

Treatment and study plan

Manganese omission

Other

Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.

5 mCg/kg/day manganese from "Multitrace-4 Neonatal."

Other

5 mCg/kg/day manganese from "Multitrace-4 Neonatal."

Primary outcomes

  1. Whole Blood Manganese

    Time frame: Baseline

    concentration of manganese in blood

  2. Whole Blood Manganese

    Time frame: 2 weeks of age

    concentration of manganese in blood

  3. Whole Blood Manganese

    Time frame: 8 weeks of age

    concentration of manganese in blood

Sponsors and collaborators

Lead sponsor

Sharp HealthCare

Other

Collaborators

  • Food and Drug Administration (FDA)

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Feb 6, 2020
Registry last updated
Aug 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.